Afroditi Boulougoura1, Irini Sereti. 1. HIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: This article explores new data from recent studies addressing the role of coinfections in immune activation in HIV-1-infected patients, with a focus on immune reconstitution inflammatory syndrome (IRIS), an aberrant inflammatory response occurring shortly after antiretroviral therapy (ART) initiation. RECENT FINDINGS: Chronic HIV infection is associated with several coinfections that contribute to immune activation in various settings including early after ART initiation in the most noticeable form of IRIS and also in chronic-treated infection, with chronic viral infections like cytomegalovirus and hepatitis C or hepatitis B virus contributing to immune activation and also morbidity and mortality. Expanding on older studies, the role of T cells in IRIS has been further elucidated with evidence of more pronounced effector activity in patients with IRIS that may be leading to excessive tissue disorder. Newer studies are also continuing to shed light on the role of myeloid cells as well as the contribution of antigen load in IRIS. In addition, preliminary data are beginning to suggest a possible role of inflammasome formation in IRIS. In cryptococcal IRIS, the role of activated immune cells (T cell and myeloid) and biomarkers were evaluated in more detail at the site of infection (cerebrospinal fluid). Finally, important differences of patients developing IRIS versus those who die from tuberculosis despite ART initiation were reported, a distinction that may have important implications for participant selection in studies aiming to prevent IRIS with immunosuppressive agents. SUMMARY: Better understanding of the role of opportunistic infections at ART initiation and IRIS pathogenesis will assist in improved strategies for prevention and treatment. The long-term consequences of IRIS remain unclear. Chronic viral coinfections with herpesviruses and hepatitis C virus are important factors in persistent immune activation in chronic-treated HIV.
PURPOSE OF REVIEW: This article explores new data from recent studies addressing the role of coinfections in immune activation in HIV-1-infectedpatients, with a focus on immune reconstitution inflammatory syndrome (IRIS), an aberrant inflammatory response occurring shortly after antiretroviral therapy (ART) initiation. RECENT FINDINGS:Chronic HIV infection is associated with several coinfections that contribute to immune activation in various settings including early after ART initiation in the most noticeable form of IRIS and also in chronic-treated infection, with chronic viral infections like cytomegalovirus and hepatitis C or hepatitis B virus contributing to immune activation and also morbidity and mortality. Expanding on older studies, the role of T cells in IRIS has been further elucidated with evidence of more pronounced effector activity in patients with IRIS that may be leading to excessive tissue disorder. Newer studies are also continuing to shed light on the role of myeloid cells as well as the contribution of antigen load in IRIS. In addition, preliminary data are beginning to suggest a possible role of inflammasome formation in IRIS. In cryptococcal IRIS, the role of activated immune cells (T cell and myeloid) and biomarkers were evaluated in more detail at the site of infection (cerebrospinal fluid). Finally, important differences of patients developing IRIS versus those who die from tuberculosis despite ART initiation were reported, a distinction that may have important implications for participant selection in studies aiming to prevent IRIS with immunosuppressive agents. SUMMARY: Better understanding of the role of opportunistic infections at ART initiation and IRIS pathogenesis will assist in improved strategies for prevention and treatment. The long-term consequences of IRIS remain unclear. Chronic viral coinfections with herpesviruses and hepatitis C virus are important factors in persistent immune activation in chronic-treated HIV.
Authors: Anne Bourgarit; Guislaine Carcelain; Valerie Martinez; Caroline Lascoux; Veronique Delcey; Brigitte Gicquel; Eric Vicaut; Philippe H Lagrange; Daniel Sereni; Brigitte Autran Journal: AIDS Date: 2006-01-09 Impact factor: 4.177
Authors: Zuri A Sullivan; Emily B Wong; Thumbi Ndung'u; Victoria O Kasprowicz; William R Bishai Journal: EBioMedicine Date: 2015-04-01 Impact factor: 8.143
Authors: Bruno B Andrade; Amrit Singh; Gopalan Narendran; Melissa E Schechter; Kaustuv Nayak; Sudha Subramanian; Selvaraj Anbalagan; Stig M R Jensen; Brian O Porter; Lis R Antonelli; Katalin A Wilkinson; Robert J Wilkinson; Graeme Meintjes; Helen van der Plas; Dean Follmann; Daniel L Barber; Soumya Swaminathan; Alan Sher; Irini Sereti Journal: PLoS Pathog Date: 2014-10-02 Impact factor: 6.823
Authors: Graeme Meintjes; Katalin Andrea Wilkinson; Molebogeng Xheeda Rangaka; Keira Skolimowska; Kerryn van Veen; Musaed Abrahams; Ronnett Seldon; Dominique J Pepper; Kevin Rebe; Priscilla Mouton; Gilles van Cutsem; Mark Patrick Nicol; Gary Maartens; Robert John Wilkinson Journal: Am J Respir Crit Care Med Date: 2008-08-28 Impact factor: 21.405
Authors: Emilio Letang; James J Lewis; Mark Bower; Anisa Mosam; Margareth Borok; Thomas B Campbell; Denise Naniche; Tom Newsom-Davis; Fahmida Shaik; Suzanne Fiorillo; Jose M Miro; David Schellenberg; Philippa J Easterbrook Journal: AIDS Date: 2013-06-19 Impact factor: 4.177
Authors: David B Meya; Samuel Okurut; Godfrey Zziwa; Melissa A Rolfes; Melander Kelsey; Steve Cose; Moses Joloba; Prossy Naluyima; Brent E Palmer; Andrew Kambugu; Harriet Mayanja-Kizza; Paul R Bohjanen; Michael A Eller; Sharon M Wahl; David R Boulware; Yuka C Manabe; Edward N Janoff Journal: J Infect Dis Date: 2014-12-09 Impact factor: 5.226
Authors: Maura Manion; Dimana Dimitrova; Luxin Pei; Juan Gea-Banacloche; Adrian Zelazny; Andrea Lisco; Christa Zerbe; Alexandra F Freeman; Steven M Holland; Christopher G Kanakry; Jennifer A Kanakry; Irini Sereti Journal: Clin Infect Dis Date: 2020-02-03 Impact factor: 9.079
Authors: Diane Carnathan; Benton Lawson; Joana Yu; Kalpana Patel; James M Billingsley; Gregory K Tharp; Olivia M Delmas; Reem Dawoud; Peter Wilkinson; Charles Nicolette; Mark J Cameron; Rafick-Pierre Sekaly; Steven E Bosinger; Guido Silvestri; Thomas H Vanderford Journal: J Virol Date: 2018-04-13 Impact factor: 5.103
Authors: Caian L Vinhaes; Virginia Sheikh; Deivide Oliveira-de-Souza; Jing Wang; Adam Rupert; Gregg Roby; María B Arriaga; Kiyoshi F Fukutani; Fred Sawe; Doug Shaffer; Jintanat Ananworanich; Nittaya Phanuphak; Bruno B Andrade; Irini Sereti Journal: J Infect Dis Date: 2021-04-08 Impact factor: 5.226